RaySearch Laboratories AB (STU:27R) Cyclically Adjusted Revenue per Share: €2.64 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:27R RaySearch Laboratories AB STU:27R
84 GF Score
Price €15.34
GF Value €17.37
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB Cyclically Adjusted Revenue per Share?

RaySearch Laboratories AB STU:27R +0.51% 84 Cyclically Adjusted Revenue per Share is €2.64 as of Jun. 2026. GuruFocus rates STU:27R with a GF Score™ of 84/100 and a GF Value™ of €17.37 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

RaySearch Laboratories AB's adjusted revenue per share for the three months ended in Jun. 2026 was €0.731. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.64 for the trailing ten years ended in Jun. 2026.

During the past 12 months, RaySearch Laboratories AB's average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of RaySearch Laboratories AB was 18.70% per year. The lowest was 12.50% per year. And the median was 17.15% per year.

As of today (2026-09-22), RaySearch Laboratories AB's current stock price is €15.34. RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €2.64. RaySearch Laboratories AB's Cyclically Adjusted PS Ratio of today is 5.81.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of RaySearch Laboratories AB was 30.47. The lowest was 2.64. And the median was 7.02.


RaySearch Laboratories AB  (STU:27R) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

RaySearch Laboratories AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=15.34/2.64
=5.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of RaySearch Laboratories AB was 30.47. The lowest was 2.64. And the median was 7.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Related Terms


RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Chart

RaySearch Laboratories AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 1.88 2.13 2.33 2.53

RaySearch Laboratories AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 2.51 2.55 2.60 2.64

STU:27R vs VEEV, BTSG, TEM: Cyclically Adjusted Revenue per Share Comparison

For the Health Information Services subindustry, RaySearch Laboratories AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaySearch Laboratories AB Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where RaySearch Laboratories AB's Cyclically Adjusted PS Ratio falls into.


STU:27R
84GF Score
RaySearch Laboratories AB STU:27R
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaySearch Laboratories AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, RaySearch Laboratories AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.731/134.6100*134.6100
=0.731

Current CPI (Jun. 2026) = 134.6100.

RaySearch Laboratories AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.386 101.138 0.514
201612 0.572 102.022 0.755
201703 0.389 102.022 0.513
201706 0.427 102.752 0.559
201709 0.341 103.279 0.444
201712 0.610 103.793 0.791
201803 0.340 103.962 0.440
201806 0.398 104.875 0.511
201809 0.422 105.679 0.538
201812 0.620 105.912 0.788
201903 0.485 105.886 0.617
201906 0.521 106.742 0.657
201909 0.395 107.214 0.496
201912 0.642 107.766 0.802
202003 0.571 106.563 0.721
202006 0.448 107.498 0.561
202009 0.335 107.635 0.419
202012 0.454 108.296 0.564
202103 0.467 108.360 0.580
202106 0.444 108.928 0.549
202109 0.390 110.338 0.476
202112 0.541 112.486 0.647
202203 0.579 114.825 0.679
202206 0.446 118.384 0.507
202209 0.579 122.296 0.637
202212 0.705 126.365 0.751
202303 0.599 127.042 0.635
202306 0.609 129.407 0.633
202309 0.627 130.224 0.648
202312 0.762 131.912 0.778
202403 0.665 132.205 0.677
202406 0.808 132.716 0.820
202409 0.747 132.304 0.760
202412 0.818 132.987 0.828
202503 0.861 132.825 0.873
202506 0.812 133.699 0.818
202509 0.871 133.480 0.878
202512 1.000 133.380 1.009
202603 0.792 133.550 0.798
202606 0.731 134.610 0.731

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.64 mean?
RaySearch Laboratories AB (STU:27R) has a Cyclically Adjusted Revenue per Share of €2.64 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on RaySearch Laboratories AB and its competitors.
Is RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share too high?
RaySearch Laboratories AB's current Cyclically Adjusted Revenue per Share is €2.64. Overall, RaySearch Laboratories AB has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share compare to VEEV and BTSG?
RaySearch Laboratories AB's Cyclically Adjusted Revenue per Share of €2.64 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on RaySearch Laboratories AB and its competitors. RaySearch Laboratories AB's current Cyclically Adjusted Revenue per Share is €2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (STU:27R) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.37, compared to a current price of €15.34 — trading 11.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.64. RaySearch Laboratories AB's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For RaySearch Laboratories AB (STU:27R), the current Cyclically Adjusted Revenue per Share is €2.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaySearch Laboratories AB (STU:27R) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be undervalued. The current stock price of €15.34 is trading 11.7% below its estimated GF Value™ of €17.37. GuruFocus considers RaySearch Laboratories AB to be Modestly Undervalued.

Key valuation signals for STU:27R:

  • Cyclically Adjusted Revenue per Share: €2.64
  • GF Value™: €17.37 vs. price of €15.34 (11.7% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the STU:27R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Swedish medical technology company that develops software for radiation therapy and oncology. Its core products are the RayStation treatment planning system, which supports external beam and brachytherapy planning, and RayCare, an oncology information system that coordinates clinical workflows. The company also offers RayCommand for treatment machine control and RayIntelligence, a cloud-based analytics platform. Customers are primarily hospitals, cancer clinics, and radiotherapy departments worldwide. RaySearch sells directly in several markets and through licensing and distribution agreements with medical device manufacturers, which integrate its algorithms into their systems. Revenue comes from software licenses, support and maintenance subscriptions, and service agreements. Geographically, it operates across the Americas, Europe, Asia-Pacific and the Middle East, and other regions, with a significant share of sales outside Sweden. The company was founded in 2000 and is headquartered in Stockholm.
84GF Score

Get the complete analysis for STU:27R

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.34
Price
€17.37
GF Value